---
title: "Lilly Breaks Ground on $6.5 Billion to Supply the Pill Boom Medicare Is Funding"
description: "Medicare's Bridge program put 700,000 seniors on GLP-1s in three months, and 70% of them landed on Lilly drugs. A $6.5 billion Houston plant is the company's hedge on a pill shift Novo currently dominates."
publisher: "The Inference"
section: "Health"
published: 2026-09-24T18:15:19.462Z
modified: 2026-09-24T18:15:19.462Z
canonical: https://theinference.org/article/lilly-breaks-ground-on-6-5-billion-to-supply-the-pill-boom-medicare-is-funding
language: en
keywords: "Eli Lilly, Novo Nordisk, Obesity Drugs, Medicare, Manufacturing, Health Policy"
---

# Lilly Breaks Ground on $6.5 Billion to Supply the Pill Boom Medicare Is Funding

> Medicare's Bridge program put 700,000 seniors on GLP-1s in three months, and 70% of them landed on Lilly drugs. A $6.5 billion Houston plant is the company's hedge on a pill shift Novo currently dominates.

[Lilly](https://theinference.org/markets/companies/eli-lilly) [broke ground on Monday](https://rebusinessonline.com/eli-lilly-breaks-ground-on-6-5b-glp-1-manufacturing-facility-in-northeast-houston/) on a $6.5 billion, one-million-square-foot plant at Generation Park in northeast Houston, the largest project of its kind in Texas history [1][2][3]. Its main job is the active ingredient for Foundayo, the obesity pill that launched in April, months behind [Novo's](https://theinference.org/markets/companies/novo-nordisk) [1][4]. First product is due by 2030 [1].

## The payer built the demand first

Medicare's Bridge program [started covering obesity drugs in July at a $50 monthly co-pay](https://www.cnbc.com/2026/09/21/eli-lilly-ceo-david-ricks-glp-1s-medicare-coverage.html), across roughly 66 million beneficiaries [4]. Since then, 700,000 seniors have started GLP-1s, and 70% are on Lilly medicines, most still on the Zepbound injection [4]. One in three new pill patients takes Foundayo, a share CEO Dave Ricks says grows every week [1][4].

## Novo owns the pill, and still got marked down

Novo's London strategy day landed the same morning. Chief executive Mike Doustdar [forecast pills could take half the obesity market by 2030](https://tradersunion.com/news/financial-news/show/3435457-novo-nordisk-obesity-pills-market-2030/), above Wall Street's 14 to 40%, and pointed to more than 80% of new US oral prescriptions plus $843 million in first-half oral Wegovy sales [5]. [The stock still fell as much as 7%](https://finance.yahoo.com/markets/stocks/articles/novo-nordisk-stock-falls-2030-111924503.html): semaglutide loses US exclusivity in 2032, and 2026 sales guidance runs flat to down 6% [6]. Lilly holds about 61% of the whole market [6].

![Four boxes of Novo Nordisk's Wegovy (semaglutide) injection pens in different doses stacked on a pharmacy counter](https://storage.googleapis.com/theinference-public/img/4bcdec7040f1a7e3.jpg)

*Novo Nordisk's Wegovy injection pens. Novo's oral version of semaglutide currently leads the obesity pill market that Lilly's Houston plant is built to contest. (Nelson R. de Lima Filho via Wikimedia Commons)*

## The capex is the insurance policy

Lilly has committed more than $50 billion to US manufacturing since 2020, with Houston one of 10 sites underway [1][2]. Quarterly capex has tripled, from $0.97 billion in late 2023 to $2.93 billion in the second quarter, when revenue reached $22.97 billion, up 47.7% [7]. Foundayo itself booked $98 million in its debut quarter [1]. The point of the shovels is a pill boom that cannot outrun Lilly's supply.

*Chart: **Quarterly capex has tripled since 2023, to $2.93B** Line chart of Eli Lilly quarterly capital spending from Q3 2023 to Q2 2026, rising from about $1 billion to $2.9 billion*

*Quarterly capital spending, US$ billions, from Eli Lilly's SEC filings via Sharadar, Q3 2023 through Q2 2026. February 2025 four-site commitment per CNBC. [1][7]*

## The multiple already assumes the win

Tuesday brought the reminder that convenience cuts both ways: [Viking's VK2735 held 97% of prior weight loss on every-other-week injections](https://www.rttnews.com/3692907/viking-s-vk2735-shows-strong-weight-loss-maintenance-with-less-frequent-dosing-stock-up.aspx), against 61% on placebo, and VKTX jumped 35% [8][9]. Phase 3, regulators, manufacturing scale and payer access still separate that data from a genuine threat [10]. Lilly trades near 40 times trailing earnings, up about 8% in 2026 against the S&P 500's 13% [11], on guided revenue of $85 to $87 billion and Ken Langone's call for $2,000 within four years [12]. Next readings: Foundayo filings in more than 40 countries ahead of a 2027 global rollout [2], and Novo's pledge to build oral capacity for 10 times as many patients [6]. Medicare funds the demand; the concrete is certain; the multiple is a belief.

## Takeaway

Medicare's Bridge program created the GLP-1 demand shock, and Lilly's $6.5 billion Houston plant is its bet that the pill market keeps growing faster than supply. The concrete is certain; the 40-times multiple is the belief.

## Sources

1. [CNBC, "Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production", 21 September 2026](https://www.cnbc.com/2026/09/21/lilly-is-ramping-up-future-manufacturing-for-foundayo-obesity-pill.html)
2. [REBusiness, "Eli Lilly Breaks Ground on $6.5B GLP-1 Manufacturing Facility in Northeast Houston", 22 September 2026](https://rebusinessonline.com/eli-lilly-breaks-ground-on-6-5b-glp-1-manufacturing-facility-in-northeast-houston/)
3. [Houston Business Journal, "Eli Lilly breaks ground on $6.5B Houston plant, largest project of its kind in Texas history", 21 September 2026](https://www.bizjournals.com/houston/news/2026/09/21/eli-lilly-breaks-ground-manufacturing-facility.html)
4. [CNBC, "Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs", 21 September 2026](https://www.cnbc.com/2026/09/21/eli-lilly-ceo-david-ricks-glp-1s-medicare-coverage.html)
5. [Traders Union, "Novo Nordisk sees weight-loss pills capturing half of obesity drug market by 2030", 22 September 2026](https://tradersunion.com/news/financial-news/show/3435457-novo-nordisk-obesity-pills-market-2030/)
6. [Quartz via Yahoo Finance, "Novo Nordisk stock falls after 2030 strategy disappoints investors", 21 September 2026](https://finance.yahoo.com/markets/stocks/articles/novo-nordisk-stock-falls-2030-111924503.html)
7. [Sharadar quarterly fundamentals from Eli Lilly's SEC filings, retrieved 24 September 2026](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478)
8. [RTTNews, "Viking's VK2735 Shows Strong Weight-Loss Maintenance With Less Frequent Dosing; Stock Up", 22 September 2026](https://www.rttnews.com/3692907/viking-s-vk2735-shows-strong-weight-loss-maintenance-with-less-frequent-dosing-stock-up.aspx)
9. [Yahoo Finance (StockTwits), "VKTX Stock Spikes 38% Premarket: Viking's VK2735 Shows Promise For Weight-Loss Maintenance", 22 September 2026](https://finance.yahoo.com/healthcare/articles/vktx-stock-spikes-38-premarket-120819099.html)
10. [Yahoo Finance (GuruFocus), "Lilly Rises Higher as Viking Preserves Up to 90% Monthly", 22 September 2026](https://finance.yahoo.com/markets/stocks/articles/lilly-rises-higher-viking-preserves-213539303.html)
11. [NAI500, "Eli Lilly Stock Trails the Market, and Its Growth Story Faces a Test Under a High Valuation", 23 September 2026](https://nai500.com/blog/2026/09/eli-lilly-stock-trails-the-market-and-its-growth-story-faces-a-test-under-a-high-valuation/)
12. [24/7 Wall St., "His Bet On Home Depot Made Ken Langone A Billionaire. Now He Sees Eli Lilly Stock Hitting $2,000", 22 September 2026](https://247wallst.com/investing/2026/09/22/his-bet-on-home-depot-made-ken-langone-a-billionaire-now-he-sees-eli-lilly-stock-hitting-2000/)


---

Lilly Breaks Ground on $6.5 Billion to Supply the Pill Boom Medicare Is Funding — The Inference. Canonical: https://theinference.org/article/lilly-breaks-ground-on-6-5-billion-to-supply-the-pill-boom-medicare-is-funding
